Advanced Solid Tumours and Lymphomas
OSE Immunotherapeutics supports clinical research in advanced solid tumours and lymphomas, with attention to patients whose disease has progressed after prior treatment. The sponsor’s portfolio includes studies of immune-based cancer therapies across a broad range of oncology settings.
- Advanced solid tumours
- Lymphomas
- Immunotherapy-resistant disease
Research activity in this area reflects a focus on difficult-to-treat malignancies in Europe and other active international sites.
Non-Small Cell Lung Cancer
The sponsor is actively involved in studies for metastatic non-small cell lung cancer, including populations defined by HLA-A2 positive phenotype and prior exposure to immunotherapy. This area represents a major therapeutic interest in advanced lung cancer management.
- Metastatic NSCLC
- HLA-A2 positive phenotype
- Post-immunotherapy treatment
Clinical work in this field includes evaluation of cancer immunotherapy approaches for patients with late-stage lung malignancy.
Cancer Vaccines
OSE Immunotherapeutics has research interests in therapeutic cancer vaccines, with a specific focus on immune-directed treatment strategies for advanced malignancies. This includes investigation of vaccine-based approaches in solid tumour settings.
- Therapeutic cancer vaccines
- Immune activation in cancer
- Advanced solid tumour treatment
This therapeutic domain aligns with the sponsor’s broader work in oncology immunotherapy.
Immune Checkpoint Therapies
The sponsor is engaged in research on PD-1 blocking monoclonal antibodies and combination immune checkpoint strategies. These studies address immune modulation in both solid tumours and lymphoid malignancies.
- PD-1 blockade
- Monoclonal antibody therapy
- Combination immunotherapy
Current activity spans multiple international research sites, supporting development in immuno-oncology.
